Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High?
The mean of analysts' price targets for Nektar (NKTR) points to a 50% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief Research & Development Officer Korin Franklin - Corporate Participant Sandra A.
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $2.95 per share versus the Zacks Consensus Estimate of a loss of $3.13. This compares to a loss of $3.75 per share a year ago.
3 Bullish Biotech Stocks With Explosive Growth Trends
Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp movement.
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a small number of drug candidates and lacking a means of achieving profitability until one or more of those products make it to market.
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
On June 24, Nektar Therapeutics NASDAQ: NKTR stock exploded nearly 157% following news that Rezpeg, the company's experimental treatment for atopic dermatitis (eczema), successfully met its primary and secondary goals in a Phase 2b trial. Nektar joined a wave of micro-cap biotechnology stocks surging after promising clinical trial results.
Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg
Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.
Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?
Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today's trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for treating moderate-to-severe atopic dermatitis (eczema), marking a pivotal moment for the cash-strapped biotech company. The study met both primary and secondary endpoints, validating the company's novel regulatory T-cell approach to treating inflammatory skin conditions.
Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC
Results from Nektar Therapeutics' phase 2b REZOLVE-AD study, using REZPEG for the treatment of patients with atopic dermatitis, are expected in June 2025. The global atopic dermatitis treatment market is projected to reach $28.7 billion by 2031. NKTR's results from phase 2b REZOLVE-AA, using REZPEG for the treatment of patients with Alopecia Areata, expected in the 2nd half of 2025.
